Terms: = Endocrine gland cancer AND KDR, VEGFR2, 3791, ENSG00000128052, P35968, VEGFR, CD309, FLK1
543 results:
1. Circulating Tumor DNA Dynamics Fail to Predict Efficacy of Poly(ADP-ribose) Polymerase/vegfr Inhibition in Patients With Heavily Pretreated Advanced Solid Tumors.
Hu Y; Narayan A; Xu Y; Wolfe J; Vu D; Trinh T; Kantak C; Ivy SP; Eder JP; Deng Y; LoRusso P; Kim JW; Patel AA
JCO Precis Oncol; 2024 Feb; 8():e2300289. PubMed ID: 38412387
[TBL] [Abstract] [Full Text] [Related]
2. Combined inhibition of HER2 and vegfr synergistically improves therapeutic efficacy via PI3K-AKT pathway in advanced ovarian cancer.
Li W; Zhang K; Wang W; Liu Y; Huang J; Zheng M; Li L; Zhang X; Xu M; Chen G; Wang L; Zhang S
J Exp Clin Cancer Res; 2024 Feb; 43(1):56. PubMed ID: 38403634
[TBL] [Abstract] [Full Text] [Related]
3. Anti-tumorigenic effects of naive and TLR4-primed adipose-derived mesenchymal stem cells on pancreatic ductal adenocarcinoma cells.
Kaçaroğlu D; Yaylacı S; Gurbuz N
Cancer Med; 2024 Jan; 13(2):e6964. PubMed ID: 38379331
[TBL] [Abstract] [Full Text] [Related]
4. Prevalence and management of proteinuria associated with vascular endothelial growth factor receptor-targeted tyrosine kinase inhibitor treatment in advanced renal cell carcinoma, hepatocellular carcinoma, and thyroid cancer.
Kato T; Mizuno R; Miyake H
Int J Urol; 2024 May; 31(5):465-474. PubMed ID: 38318663
[TBL] [Abstract] [Full Text] [Related]
5. Efficacy and safety of VEGF/vegfr inhibitors for platinum-resistant ovarian cancer: a systematic review and meta-analysis of randomized controlled trials.
Huang D; Ke L; Cui H; Li S; Sun F
BMC Womens Health; 2024 Jan; 24(1):34. PubMed ID: 38218775
[TBL] [Abstract] [Full Text] [Related]
6. Apatinib weakens proliferation, migration, invasion, and angiogenesis of thyroid cancer cells through downregulating pyruvate kinase M2.
Yang X; Li W; Han X; Wang J; Dai J; Ye X; Meng M
Sci Rep; 2024 Jan; 14(1):879. PubMed ID: 38195651
[TBL] [Abstract] [Full Text] [Related]
7. Integration of scRNA and bulk RNA-sequence to construct the 5-gene molecular prognostic model based on the heterogeneity of thyroid carcinoma endothelial cell.
Ni Z; Cong S; Li H; Liu J; Zhang Q; Wei C; Pan G; He H; Liu W; Mao A
Acta Biochim Biophys Sin (Shanghai); 2024 Feb; 56(2):255-269. PubMed ID: 38186223
[TBL] [Abstract] [Full Text] [Related]
8. The importance of early-stage blood pressure control in thyroid cancer patients treated with lenvatinib from the perspective of dose intensity.
Masaki C; Shioya J; Sugino K; Terasawa Y; Yokotsuka S; Nakata M; Kitagawa W; Ito K
Support Care Cancer; 2023 Nov; 31(12):729. PubMed ID: 38017341
[TBL] [Abstract] [Full Text] [Related]
9. Hypoxia-activated prodrug and antiangiogenic therapies cooperatively treat pancreatic cancer but elicit immunosuppressive G-MDSC infiltration.
Liu A; Gammon ST; Pisaneschi F; Boda A; Ager CR; Piwnica-Worms D; Hong DS; Curran MA
JCI Insight; 2024 Jan; 9(1):. PubMed ID: 37988164
[TBL] [Abstract] [Full Text] [Related]
10. Tumor Explants Elucidate a Cascade of Paracrine SHH, WNT, and VEGF Signals Driving Pancreatic cancer Angiosuppression.
Hasselluhn MC; Decker-Farrell AR; Vlahos L; Thomas DH; Curiel-Garcia A; Maurer HC; Wasko UN; Tomassoni L; Sastra SA; Palermo CF; Dalton TC; Ma A; Li F; Tolosa EJ; Hibshoosh H; Fernandez-Zapico ME; Muir A; Califano A; Olive KP
Cancer Discov; 2024 Feb; 14(2):348-361. PubMed ID: 37966260
[TBL] [Abstract] [Full Text] [Related]
11. Early Increases in Blood Pressure and Major Adverse Cardiovascular Events in Patients With Renal Cell Carcinoma and Thyroid cancer Treated With vegfr TKIs.
Narayan V; Liu T; Song Y; Mitchell J; Sicks J; Gareen I; Sun L; Denduluri S; Fisher C; Manikowski J; Wojtowicz M; Vadakara J; Haas N; Margulies KB; Ky B
J Natl Compr Canc Netw; 2023 Oct; 21(10):1039-1049.e10. PubMed ID: 37856199
[TBL] [Abstract] [Full Text] [Related]
12. Association of kdr (rs2071559, rs1870377), CFH (rs1061170, rs1410996) genes variants and serum levels with pituitary adenoma.
Bruzaite A; Gedvilaite G; Kriauciuniene L; Liutkeviciene R
Mol Genet Genomic Med; 2024 Jan; 12(1):e2289. PubMed ID: 37803932
[TBL] [Abstract] [Full Text] [Related]
13. A novel chiral oxazoline copper(II)-based complex inhibits ovarian cancer growth
Fan R; Wei JC; Xu BB; Jin N; Gong XY; Qin XY
Dalton Trans; 2023 Aug; 52(33):11427-11440. PubMed ID: 37539728
[TBL] [Abstract] [Full Text] [Related]
14. In Vivo Ultrasound Molecular Imaging in the Evaluation of Complex Ovarian Masses: A Practical Guide to Correlation with Ex Vivo Immunohistochemistry.
Antil N; Wang H; Kaffas AE; Desser TS; Folkins A; Longacre T; Berek J; Lutz AM
Adv Biol (Weinh); 2023 Aug; 7(8):e2300091. PubMed ID: 37403275
[TBL] [Abstract] [Full Text] [Related]
15. Dynamic contrast-enhanced MRI to characterize angiogenesis in primary epithelial ovarian cancer: An exploratory study.
Lindgren A; Anttila M; Arponen O; Hämäläinen K; Könönen M; Vanninen R; Sallinen H
Eur J Radiol; 2023 Aug; 165():110925. PubMed ID: 37320880
[TBL] [Abstract] [Full Text] [Related]
16. Phase II randomised, double-blind study of mFOLFIRINOX plus ramucirumab versus mFOLFIRINOX plus placebo in advanced pancreatic cancer patients (HCRN GI14-198).
Shaib WL; Manali R; Liu Y; El-Rayes B; Loehrer P; O'Neil B; Cohen S; Khair T; Robin E; Huyck T; Bekaii-Saab T
Eur J Cancer; 2023 Aug; 189():112847. PubMed ID: 37268519
[TBL] [Abstract] [Full Text] [Related]
17. Mass Spectrometry-Based Proteomics of Epithelial Ovarian cancers: A Clinical Perspective.
Qian L; Sun R; Xue Z; Guo T
Mol Cell Proteomics; 2023 Jul; 22(7):100578. PubMed ID: 37209814
[TBL] [Abstract] [Full Text] [Related]
18. Angiogenesis inhibitors for the treatment of epithelial ovarian cancer.
Gaitskell K; Rogozińska E; Platt S; Chen Y; Abd El Aziz M; Tattersall A; Morrison J
Cochrane Database Syst Rev; 2023 Apr; 4(4):CD007930. PubMed ID: 37185961
[TBL] [Abstract] [Full Text] [Related]
19. A multicenter, open-label, randomized, phase II study of cediranib with or without lenalidomide in iodine 131-refractory differentiated thyroid cancer.
Rosenberg AJ; Liao CY; Karrison T; de Souza JA; Worden FP; Libao B; Krzyzanowska MK; Hayes DN; Winquist E; Saloura V; Prescott K; Villaflor VM; Seiwert TY; Schechter RB; Stadler WM; Cohen EEW; Vokes EE
Ann Oncol; 2023 Aug; 34(8):714-722. PubMed ID: 37182801
[TBL] [Abstract] [Full Text] [Related]
20. Molecular cluster mining of high-grade serous ovarian cancer via multi-omics data analysis aids precise medicine.
Cai D; Liu T; Fang J; Liu Y
J Cancer Res Clin Oncol; 2023 Sep; 149(11):9151-9165. PubMed ID: 37178426
[TBL] [Abstract] [Full Text] [Related]
[Next]
